Company
Exela Pharma
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
12
6 still marketed
Novel approvals
0
Approvals since 2021
4
Originals and new uses
Phase 3 trials
2
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Glyrx-Pf new use Jul 16, 2025
- Fentanyl Citrate approved Feb 8, 2023
- Midazolam In 0.8% Sodium Chloride approved Jul 20, 2022
- Diltiazem Hydrochloride In Dextrose 5% approved Oct 28, 2021
- Elcys approved Priority reviewApr 16, 2019
- Tranexamic Acid approved Apr 15, 2019
- Glyrx-Pf approved Jul 11, 2018
- Glyrx-Pf approved Jul 11, 2018
- Nipride Rtu In Sodium Chloride 0.9% approved Mar 8, 2017
- Ganzyk-Rtu approved Feb 17, 2017
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (6)
Newest FDA action first.
- Glyrx-Pf Glycopyrrolate · 2018
- Elcys Cysteine Hydrochloride · 2019
- Akovaz Ephedrine Sulfate · 2016
- Tranexamic Acid Tranexamic Acid · 2019
- Nipride Rtu In Sodium Chloride 0.9% Sodium Nitroprusside · 2017
- Verapamil Hydrochloride Verapamil Hydrochloride · 1984
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.